Two Sigma Advisers’s AbbVie ABBV Stock Holding History

Two Sigma Advisers’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-165,444	Closed	-$37.8M	–	7
2025 Q4	$37.8M	Buy	165,444 +106,100	+179%	+$24.2M	0.07%	223
2025 Q3	$13.7M	Buy	59,344 +45,700	+335%	+$9.31M	0.03%	415
2025 Q2	$2.53M	Buy	13,644 +9,300	+214%	+$1.73M	0.01%	1009
2025 Q1	$910K	Buy	+4,344	New	+$844K	﹤0.01%	1515
2024 Q3	–	Sell	-250,244	Closed	-$42.9M	–	2261
2024 Q2	$42.9M	Sell	250,244 -216,500	-46%	-$35.9M	0.1%	200
2024 Q1	$85M	Sell	466,744 -577,200	-55%	-$99.5M	0.2%	112
2023 Q4	$162M	Sell	1,043,944 -431,200	-29%	-$62.9M	0.38%	61
2023 Q3	$220M	Buy	1,475,144 +248,100	+20%	+$36.4M	0.56%	38
2023 Q2	$165M	Buy	1,227,044 +527,600	+75%	+$77.4M	0.42%	63
2023 Q1	$111M	Buy	699,444 +666,600	+2,030%	+$102M	0.29%	85
2022 Q4	$5.31M	Sell	32,844 -160,122	-83%	-$24.6M	0.01%	761
2022 Q3	$25.9M	Sell	192,966 -152,000	-44%	-$21.8M	0.08%	259
2022 Q2	$52.8M	Sell	344,966 -1,853,978	-84%	-$283M	0.15%	149
2022 Q1	$356M	Buy	2,198,944 +92,778	+4%	+$13.5M	0.95%	15
2021 Q4	$285M	Buy	2,106,166 +1,704,209	+424%	+$201M	0.71%	32
2021 Q3	$43.4M	Sell	401,957 -2,044,510	-84%	-$234M	0.11%	181
2021 Q2	$276M	Sell	2,446,467 -1,063,000	-30%	-$120M	0.73%	23
2021 Q1	$380M	Sell	3,509,467 -150,500	-4%	-$16.1M	1.04%	10
2020 Q4	$392M	Sell	3,659,967 -690,622	-16%	-$66.4M	1.05%	8
2020 Q3	$381M	Buy	4,350,589 +173,002	+4%	+$16.3M	1.09%	7
2020 Q2	$410M	Buy	4,177,587 +1,576,465	+61%	+$139M	1.21%	8
2020 Q1	$198M	Sell	2,601,122 -3,109,300	-54%	-$265M	0.76%	13
2019 Q4	$506M	Sell	5,710,422 -579,900	-9%	-$48.1M	1.17%	4
2019 Q3	$476M	Buy	6,290,322 +357,800	+6%	+$24.5M	1.17%	4
2019 Q2	$431M	Buy	5,932,522 +872,100	+17%	+$68.5M	1.07%	6
2019 Q1	$408M	Buy	5,060,422 +3,772,100	+293%	+$309M	1.03%	3
2018 Q4	$119M	Buy	1,288,322 +42,770	+3%	+$3.76M	0.32%	77
2018 Q3	$118M	Buy	1,245,552 +467,699	+60%	+$44.4M	0.29%	88
2018 Q2	$72.1M	Sell	777,853 -425,399	-35%	-$41.5M	0.19%	133
2018 Q1	$114M	Buy	1,203,252 +383,025	+47%	+$42.1M	0.31%	78
2017 Q4	$79.3M	Buy	820,227 +245,498	+43%	+$23.1M	0.21%	124
2017 Q3	$51.1M	Buy	574,729 +452,700	+371%	+$34.5M	0.14%	174
2017 Q2	$8.85M	Buy	122,029 +46,600	+62%	+$3.13M	0.03%	548
2017 Q1	$4.92M	Sell	75,429 -2,036,270	-96%	-$128M	0.02%	811
2016 Q4	$132M	Sell	2,111,699 -470,050	-18%	-$28.7M	0.51%	41
2016 Q3	$163M	Buy	2,581,749 +793,209	+44%	+$51.3M	0.69%	22
2016 Q2	$111M	Sell	1,788,540 -1,152,400	-39%	-$70.2M	0.56%	40
2016 Q1	$168M	Buy	2,940,940 +1,285	+0%	+$71.6K	0.94%	10
2015 Q4	$174M	Buy	2,939,655 +625,553	+27%	+$36M	1.04%	3
2015 Q3	$126M	Buy	+2,314,102	New	+$151M	0.79%	14
2015 Q2	–	Sell	-307,341	Closed	-$18M	–	1862
2015 Q1	$18M	Sell	307,341 -138,220	-31%	-$8.35M	0.13%	198
2014 Q4	$29.2M	Buy	445,561 +427,420	+2,356%	+$26.9M	0.23%	102
2014 Q3	$1.05M	Sell	18,141 -797,100	-98%	-$44.3M	0.01%	1104
2014 Q2	$46M	Buy	815,241 +554,200	+212%	+$29.1M	0.36%	56
2014 Q1	$13.4M	Sell	261,041 -264,600	-50%	-$13.4M	0.12%	183
2013 Q4	$27.8M	Buy	525,641 +3,500	+0.7%	+$172K	0.27%	76
2013 Q3	$23.4M	Buy	522,141 +424,665	+436%	+$18.8M	0.28%	75
2013 Q2	$4.03M	Buy	+97,476	New	+$4.26M	0.06%	300

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Two Sigma Advisers's ABBV Position: Q1 2026 in Review

Two Sigma Advisers sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 165,444 shares — an estimated $37.8M sold.

Two Sigma Advisers first reported a position in ABBV in Q2 2013 and held it in 48 quarters. The position peaked at $506M in Q4 2019. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Two Sigma Advisers reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 165,444 AbbVie shares in Q1 2026, an estimated $37.8M.
Two Sigma Advisers first reported a position in AbbVie in Q2 2013 and held it in 48 quarters.
Two Sigma Advisers's AbbVie position peaked at $506M in Q4 2019.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.